Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Peptide Receptor 1 (VPAC1) Targeted Detection of Genitourinary Cancer: A Urinary Assay

By January 28, 2019February 28th, 2021No Comments

Prostate cancer (CaP) and bladder urothelial cancer (BUC) are the two most common malignancies in urology, and both overexpress VPAC1. VPAC1 is overexpressed at the onset of the malignancy, prior to elevation of PSA, or alteration of cell morphology. We hypothesize that VPAC1 expressed in high density on PC and BUC can be targeted for detection of shed tumor cells (STC) in voided urine, using TP4303, a VPAC1 specific biomolecule labeled with a near infrared fluorophore.

The method is simple, noninvasive, rapid and appears to detect STC in patients with known prostate and bladder malignancy with high sensitivity. VPAC1 is a promising and novel approach for accurate and non-invasive detection of CaP and BUC from voided urine.

Read more…